ClinicalTrials.gg
CompletedNCT06508879OHSCWDUpdated Jul 18, 2024

Does Occlusive Hydrocolloid Silver-containing Wound Dressing After Sternotomy Reduce Surgical Side Infection After Cardiac Surgery?

An interventional study of Aquacel Ag Surgical® and Standard Care (sterile gauze and adhesive tape) in Surgical Site Infection; Cardiac Surgery; Advanced Dressing; Postoperative Care, sponsored by University Medical Center Mainz. Completed at 1 site in Germany. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-07-18.

Sponsored by University Medical Center Mainz · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 6 years 6 months after the study started (first participant enrolled Jan 2018, registered Jul 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Surgical Wound Infection with a site in Germany — 3 open to participants now, 3 under way, none of them phase 3. Surgical Wound Infection · Germany.

Enrollment
8th of 15
352 · median 352
Started
2018
with 2 others
No phase
9 of 22
2 open now
Registered
18th of 22
by date

Among the 22 studies in Surgical Wound Infection with a site in Germany, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2018, is one of 9 with no phase, and was the 18th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

3 of the 22 studies in Surgical Wound Infection with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Surgical Wound Infection with a site in Germany, or all of them as a file.
02

Study summary

Wound healing disorders are a major problem in cardiac surgery. They prolong the inpatient stay and are associated with a high health and, above all, psychological burden for patients. They also represent a major organizational, medical and financial challenge for the treatment team. There is therefore still a great need for effective prevention of wound healing disorders. It goes without saying that wound management plays a major role in the development of wound healing disorders. Nowadays, there are a large number of products from various manufacturers and studies for efficient wound healing disorder prophylaxis. One point of criticism is that most of the existing studies are financed by the manufacturer. Due to the otherwise broad range of applications for all wounds in various specialist areas, it remains to be clarified whether such products can achieve a reduction in the rate of wound healing disorders, especially in cardiac surgery. After extensive literature research, we are of the opinion that the Aquacel Surgical Ag dressing, a new silver-coated hydrocolloid dressing, can be offered to cardiac surgery patients at our clinic as an effective prophylaxis against wound healing disorders.The study is a randomized prospective clinical trial. It is being conducted at the Clinic for Cardiothoracic and Vascular Surgery and has already been approved by the Rhineland-Palatinate Ethics Committee. The study should include 440 heart patients and last for 12 months. It will compare the Aquacel Surgical Ag bandage against our conventional methods. This study is being conducted independently of the industry. We want to prove that an intelligent investment in the prophylaxis of wound healing disorders is worthwhile for both patients and the clinic. If the outcome of the study is positive, this dressing will be be used regularly in our cardiac surgery clinic.

03

Conditions studied

  • Surgical Site Infection; Cardiac Surgery; Advanced Dressing; Postoperative Care
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Coronary artery bypass surgery
  2. Elective and primary surgery (no reoperations)
  3. Complete median sternotomy
  4. Age under 90 years
  5. Weight in the range of 50-140kg
  6. No known allergy to silver or other wound dressings
  7. No therapy or hormonal substitution therapy, except for thyroid hormone
  8. Capacity to consent

Exclusion criteria

Exclusion Criteria:

  1. Failure of medical personnel to adhere to study protocol, e.g., not applying the right wound dressing according to study protocol
  2. Patients own decision
  3. Lack of harvesting of at least one internal thoracic artery
  4. Peri- and post-operative ventilation for >48h
  5. Re-thoracotomy for reasons other than SSI, e.g., bleeding
  6. Mortality within the first 30 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
352 participants (actual)

Study arms

  • Active comparator
    Control Group

    a standard wound dressing composed of sterile gauze and adhesive tape was applied under sterile conditions. In the absence of bleeding, excessive wound secretion, or detachment, the dressing was left on the wound until the second postoperative day (POD 2), otherwise, it was changed immediately. Starting at POD 2, the dressing was changed daily under aseptic conditions until the wound remained dry (between POD 3-5). In the absence of bleeding, excessive wound secretion, or detachment, the wound was then left uncovered. This practice corresponded to the standard treatment of cardiothoracic patients in our department at the time of initiating this study.

    Other: Standard Care (sterile gauze and adhesive tape)

  • Experimental
    Test Group

    directly after closing the wound, an occlusive hydrocolloid silver-containing wound dressing (Aquacel Ag Surgical®, ConvaTec, Oklahoma City, OK, USA) was applied under sterile conditions and, in the absence of bleeding; excessive wound secretion, or detachment, was maintained on the wound until POD 5, at which time the dressing was removed. In case of bleeding, excessive wound secretion, or detachment, the dressing was removed, the wound was cleaned, and a new sterile hydrocolloid wound dressing applied under aseptic conditions.

    Combination Product: Aquacel Ag Surgical®

Interventions

  • Combination productAquacel Ag Surgical®

    Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.

  • OtherStandard Care (sterile gauze and adhesive tape)

    Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.

06

What researchers measure

Primary outcomes

  1. SSI rate

    overall rate of incidence of any kind of SSI

    Time frame: 30 days

Secondary outcomes

  1. dressing changes

    Time frame: 7 days

  2. severity of SSI

    Time frame: 30 days

  3. need for treatment

    Time frame: 30 days

07

Study locations

1 site
  • Department of Cardiovascular Surgery, University Hospital of Johannes Gutenberg University Mainz
    Mainz, Rheinland-Pfalz 55131, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Aug 2019, 19 months.

Of 202 non-industry interventional studies with no phase under Surgical Wound Infection, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's 19 months is below that.

Counting every sponsor, half of 209 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2024
First posted
Jul 18, 2024
StartActual
Jan 1, 2018
Primary completionActual
Aug 31, 2019
CompletionActual
Aug 31, 2019
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06508879
Lead sponsor
University Medical Center Mainz
Collaborators
German Research Foundation
Responsible party
Dr. med. Kathrin Dohle (Cardiac surgery specialist, University Medical Center Mainz) — Principal investigator
First posted
Jul 18, 2024
Start date
Jan 1, 2018
Primary completion
Aug 31, 2019
Completion
Aug 31, 2019
Last update
Jul 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion